[go: up one dir, main page]

PE20230679A1 - Inhibidores heterociclicos de pad4 - Google Patents

Inhibidores heterociclicos de pad4

Info

Publication number
PE20230679A1
PE20230679A1 PE2022001712A PE2022001712A PE20230679A1 PE 20230679 A1 PE20230679 A1 PE 20230679A1 PE 2022001712 A PE2022001712 A PE 2022001712A PE 2022001712 A PE2022001712 A PE 2022001712A PE 20230679 A1 PE20230679 A1 PE 20230679A1
Authority
PE
Peru
Prior art keywords
independently
alkyl
optionally substituted
selected independently
heterocyclic
Prior art date
Application number
PE2022001712A
Other languages
English (en)
Inventor
Kumaravel Selvakumar
Venkatram Reddy Paidi
Srinivasan Thangathirupathy
Cm Vijaya Kumar
Tirupathi Rao Alajangi
Mallikarjun Reddy Sura
Krishna Mahadevu
Ramesh Kumar Sistla
Piyush Agarwal
Karuppiah Arul Mozhi Subbiah
Jalathi S Nair
Ooha Morampudi
Manoranjan Panda
Joseph A Tino
Robert J Cherney
John V Duncia
Daniel S Gardner
T G Murali Dhar
Audrey Graham Ross
Paul E Gormisky
Xiao Zhu
Boris M Seletsky
Alyssa H Antropow
Deqiang Niu
Zhengdong Zhu
Guobin Miao
Julio Hernan Cuervo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20230679A1 publication Critical patent/PE20230679A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Referido a un compuesto de la Formula I, en donde: X1 se selecciona independientemente de CR2 y N; X2 se selecciona independientemente de CR4 y N; X3 se selecciona independientemente de O y S; X4 se selecciona independientemente de CR2 y N; siempre que X1 y X4 no sean ambos N; X5 se selecciona independientemente de O y S; X6 se selecciona independientemente de CR4, y N; siempre que X2 y X6 no sean ambos N; cuando X2 y X6 son ambos CR4, uno de R4 es H; R1 se selecciona independientemente de -NH- alquilo C1-C5 opcionalmente sustituido por uno o mas sustituyentes seleccionados de F, Cl, heterociclilo de 4-10 miembros, entre otros; R2 se selecciona independientemente de H, F, Cl, alquilo C1-C4 opcionalmente sustituido por uno o mas sustituyentes seleccionados de F, Cl, y OH, y -O alquiloC1-C4; R3 se selecciona independientemente de H, F, Cl, CN, entre otros; R4 se selecciona independientemente de H, F, Cl, Br, entre otros; R5 se selecciona independientemente de H, F, Cl, Br, CN, =O, alquilo C1-C4 opcionalmente sustituido, entre otros; R6 se selecciona independientemente de H, alquilo C1-C6; R7 se selecciona independientemente de H, F, y Cl; R8 se selecciona independientemente de H, y alquilo C1-C6 opcionalmente sustituido. Un compuesto seleccionado es 5-(2-(6-((7R)-7-Amino-2-azabiciclo[2.2.1]- heptano-2-carbonil)-4-metoxi-3-metilpirazolo[1,5-a]piridin-2-il)-1-(ciclopropilmetil)-1H-pirrolo[2,3-b]piridin-6-il)isoindolin-1-ona (5). Estos compuestos heterociclicos son inhibidores de PAD4. Tambien se refiere a metodo para preparar estos compuestos y su uso de estos compuestos en el tratamiento de una enfermedad o trastorno asociado con la actividad de la enzima PAD4.
PE2022001712A 2020-02-12 2021-02-11 Inhibidores heterociclicos de pad4 PE20230679A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041006146 2020-02-12
PCT/US2021/017554 WO2021163254A1 (en) 2020-02-12 2021-02-11 Heterocyclic pad4 inhibitors

Publications (1)

Publication Number Publication Date
PE20230679A1 true PE20230679A1 (es) 2023-04-21

Family

ID=74856949

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001712A PE20230679A1 (es) 2020-02-12 2021-02-11 Inhibidores heterociclicos de pad4

Country Status (16)

Country Link
US (1) US12473304B2 (es)
EP (1) EP4103559A1 (es)
JP (1) JP7711075B2 (es)
KR (1) KR20220140795A (es)
CN (1) CN115348961B (es)
AR (1) AR121299A1 (es)
AU (1) AU2021219710A1 (es)
BR (1) BR112022015792A2 (es)
CA (1) CA3167753A1 (es)
CL (1) CL2022002148A1 (es)
CO (1) CO2022011388A2 (es)
IL (1) IL295506A (es)
MX (1) MX2022009874A (es)
PE (1) PE20230679A1 (es)
TW (1) TW202140477A (es)
WO (1) WO2021163254A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115135315B (zh) 2019-12-20 2024-11-26 米拉蒂治疗股份有限公司 Sos1抑制剂
WO2021158840A1 (en) 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
PE20230488A1 (es) 2020-04-30 2023-03-21 Gilead Sciences Inc Inhibidores macrociclicos de las peptidilarginina deiminasas
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
US12240862B2 (en) 2020-12-22 2025-03-04 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60007310D1 (de) 1999-06-04 2004-01-29 Elan Pharma Int Ltd Zusammensetzungen und methoden zur verhinderung des zelltods
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
JP5554988B2 (ja) 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US7999001B2 (en) 2007-01-15 2011-08-16 The United States Of America As Represented By The Secretary Of The Army Antiviral compounds and methods of using thereof
EP2234487A4 (en) 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
JP2010013386A (ja) 2008-07-02 2010-01-21 Fujifilm Corp 染毛剤、染毛方法およびその製造方法
WO2013040528A1 (en) 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
WO2014015905A1 (en) * 2012-07-26 2014-01-30 Glaxo Group Limited 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors
CN103030627B (zh) 2013-01-07 2017-11-10 中国科学院上海有机化学研究所 一种噻吩环/呋喃环‑杂芳环结构的合成方法
WO2014177593A1 (en) 2013-04-29 2014-11-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Amorfrutin analogs as ppargamma-modulators
US20170216252A1 (en) 2014-07-11 2017-08-03 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
KR101501091B1 (ko) 2014-09-04 2015-03-10 주식회사 해치엠엠에이 도포용 바닥재의 미끄럼방지 요철형성용 롤러장치
CA3199601A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
WO2017075694A1 (en) 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AR107030A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
KR20180098593A (ko) * 2015-12-22 2018-09-04 칸세라 아베 포유류의 히스톤 탈아세틸화효소 활성에 대한 저해제로서 유용한 바이사이클릭 하이드록사믹산
EP3419969B1 (en) 2016-02-23 2019-12-18 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4
WO2018022897A1 (en) 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
CN110248934B (zh) 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂
JP2018140974A (ja) 2017-02-28 2018-09-13 国立大学法人 奈良先端科学技術大学院大学 放射線検出方法及び放射線検出器並びに放射線検出に用いられる新規化合物
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7202360B2 (ja) 2017-08-22 2023-01-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
CN112566916B (zh) 2018-08-08 2023-10-20 百时美施贵宝公司 作为pad4抑制剂的经取代的噻吩并吡咯
KR20210042933A (ko) 2018-08-08 2021-04-20 브리스톨-마이어스 스큅 컴퍼니 Pad 효소의 벤즈이미다졸 억제제
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
MX2021001471A (es) 2018-08-08 2021-04-28 Bristol Myers Squibb Co Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
WO2021158840A1 (en) 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑

Also Published As

Publication number Publication date
BR112022015792A2 (pt) 2022-10-11
CL2022002148A1 (es) 2023-02-24
MX2022009874A (es) 2022-08-22
EP4103559A1 (en) 2022-12-21
IL295506A (en) 2022-10-01
CN115348961B (zh) 2025-03-04
WO2021163254A1 (en) 2021-08-19
JP7711075B2 (ja) 2025-07-22
AU2021219710A1 (en) 2022-10-06
KR20220140795A (ko) 2022-10-18
TW202140477A (zh) 2021-11-01
US12473304B2 (en) 2025-11-18
CN115348961A (zh) 2022-11-15
CA3167753A1 (en) 2021-08-19
JP2023515780A (ja) 2023-04-14
CO2022011388A2 (es) 2022-08-30
US20230167131A1 (en) 2023-06-01
AR121299A1 (es) 2022-05-04

Similar Documents

Publication Publication Date Title
PE20230679A1 (es) Inhibidores heterociclicos de pad4
PE20110828A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20091383A1 (es) DERIVADOS DE IMIDAZO-[1,2-a]PIRIDINA COMO INHIBIDORES DE ALK-5 Y ALK-4
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20190918A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20210658A1 (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat)
AR041347A1 (es) Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas
PE20070021A1 (es) Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
AR041374A1 (es) Derivados de 2-oxodihidropiridina n- sustituidos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20211585A1 (es) Agente profilactico o terapeutico para atrofia muscular espinal
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
PE20060316A1 (es) Derivados de prolina como inhibidores de dipeptidil peptidasa-iv
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20220277A1 (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
PE20191236A1 (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos
PE20211377A1 (es) Derivados de triazolquinoxalina adicionalmente sustituidos
PE20060875A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren